Capital Markets Day

Creo Medical Group PLC

07 November 2023

 

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Capital Markets Day

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it is hosting its Capital Markets Day today at the offices of Deutsche Numis, London at 3pm GMT.

The Company will provide greater detail on the commercial and clinical progress of its products and will feature presentations from a number of NHS clinicians who are using Creo's products in practice.  The agenda of the event will include presentations from:

·    Dr Sal Khalid, Consultant Gastroenterologist and Clinical Lead for Endoscopy at The Pennine Acute Hospitals NHS Trust: "How Speedboat Submucosal Dissection is helping Oldham tackle bowel cancer"

·   Dr Adolfo Parra-Blanco, Consultant Gastroenterologist, Hepatologist, Nottingham NHS Treatment Centre: "Why Speedboat is so effective at reducing patient complications in the Upper GI tract"

·    Mr Tom Routledge, Consultant Thoracic Surgeon, Guy's and St. Thomas' NHS Foundation Trust: "Creo Medical - A surgeon's perspective"

The event is open to institutional investors, sell-side analysts and media only. To request a place at the event, please contact Walbrook PR on [phone] or [e-mail].

No new material information will be disclosed during the event.

-Ends-

Enquiries:

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cavendish Capital Markets Limited	[phone]
Stephen Keys / Camilla Hume (NOMAD) Nigel Birks / Harriet Ward (Corporate Broking)
Michael Johnson (Sales)
Deutsche Numis (Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown	[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen / Phillip Marriage	Mob: [phone]

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 

END